当前位置: X-MOL 学术Br. J. Haematol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
New prognosis score including absolute lymphocyte/monocyte ratio, red blood cell distribution width and beta-2 microglobulin in patients with diffuse large B-cell lymphoma treated with R-CHOP: Spanish Lymphoma Group Experience (GELTAMO).
British Journal of Haematology ( IF 5.1 ) Pub Date : 2019-11-28 , DOI: 10.1111/bjh.16263
Leyre Bento 1 , Antonio Díaz-López 2 , Gilberto Barranco 2 , Ana M Martín-Moreno 2 , Mónica Baile 3 , Alejandro Martín 3 , Juan M Sancho 4 , Olga García 4 , Mario Rodríguez 5 , Jose M Sánchez-Pina 5 , Silvana Novelli 6 , Antonio Salar 7 , Mariana Bastos 8 , M José Rodríguez-Salazar 9 , Sonia González de Villambrosia 10 , Raul Córdoba 11 , M García-Recio 1 , J Martínez-Serra 1 , Raquel Del Campo 12 , Hugo Luzardo 13 , Daniel García 14 , Azueg Hong 15 , Pau Abrisqueta 16 , Jorge Sastre-Serra 17 , Pilar Roca 17 , José Rodríguez 2 , Antonio Gutiérrez 1 ,
Affiliation  

The International Prognostic Index (IPI) is the most widely used score for non-Hodgkin lymphoma but lacks the ability to identify a high-risk population in diffuse large B-cell lymphoma (DLBCL). Low absolute lymphocyte count and high monocytes have proved to be unfavourable factors. Red-cell distribution width (RDW) has been associated with inflammation and beta-2 microglobulin (B2M) with tumour load. The retrospective study included 992 patients with DLBCL treated with R-CHOP. In the multivariate analysis, age, Eastern Cooperative Oncology Group performance status (ECOG-PS), stage, bulky mass, B2M, RDW, and lymphocyte/monocyte ratio (LMR) were independently related to progression-free survival (PFS). A new prognosis score was generated with these variables including age categorized into three groups (0, 1, 2 points); ECOG ≥ 3-4 with two; stage III/IV, bulky mass, high B2M, LMR < 2·25 and RDW > 0·96 with one each; for a maximum of 9. This score could improve the discrimination of a very high-risk subgroup with five-year PFS and overall survival (OS) of 19% and 24% versus 45% and 59% of R (revised)-IPI respectively. This score also showed greater predictive ability than IPI. A new score is presented including complete blood cell count variables and B2M, which are readily available in real-life practice without additional tests. Compared to R-IPI, it shows a more precise high-risk assessment and risk discrimination for both PFS and OS.

中文翻译:

新的预后评分包括使用R-CHOP治疗的弥漫性大B细胞淋巴瘤患者的绝对淋巴细胞/单核细胞比例,红细胞分布宽度和β-2微球蛋白:西班牙淋巴瘤组经验(GELTAMO)。

国际预后指数(IPI)是非霍奇金淋巴瘤使用最广泛的评分,但缺乏鉴别弥漫性大B细胞淋巴瘤(DLBCL)高危人群的能力。低的绝对淋巴细胞计数和高的单核细胞已被证明是不利因素。红细胞分布宽度(RDW)与炎症相关,β-2微球蛋白(B2M)与肿瘤负荷相关。回顾性研究包括992例接受R-CHOP治疗的DLBCL患者。在多变量分析中,年龄,东部合作肿瘤小组的表现状态(ECOG-PS),阶段,肿块,B2M,RDW和淋巴细胞/单核细胞比率(LMR)与无进展生存期(PFS)独立相关。利用这些变量产生了新的预后评分,其中包括将年龄分为三组(0、1、2分)。ECOG≥3-4,两个;III / IV期,肿块,高B2M,LMR <2·25和RDW> 0·96,每一项;最高评分为9分。该评分可以改善对高危亚组的区分,该亚组的五年PFS和总生存(OS)分别为19%和24%,而R(修订)-IPI分别为45%和59% 。该分数还显示出比IPI更高的预测能力。提出了一个新分数,其中包括完整的血细胞计数变量和B2M,可在现实生活中轻松获得,而无需进行额外的测试。与R-IPI相比,它显示了针对PFS和OS的更精确的高风险评估和风险区分。该分数可以改善高危亚组的五年PFS,总生存率(OS)分别为19%和24%,而R(修订)-IPI分别为45%和59%。该分数还显示出比IPI更高的预测能力。提出了一个新分数,其中包括完整的血细胞计数变量和B2M,可在现实生活中轻松获得,而无需进行额外的测试。与R-IPI相比,它显示了针对PFS和OS的更精确的高风险评估和风险区分。该评分可以改善具有五年PFS和19%和24%的总生存率(OS)的R(修订)-IPI分别为45%和59%的高危亚组的辨别力。该分数还显示出比IPI更高的预测能力。提出了一个新分数,其中包括完整的血细胞计数变量和B2M,可在现实生活中轻松获得,而无需进行额外的测试。与R-IPI相比,它显示了针对PFS和OS的更精确的高风险评估和风险区分。
更新日期:2019-11-30
down
wechat
bug